Seagen Inc. entered into a commercial supply agreement dated as of July 1, 2021 with Hovione FarmaCiencia SA to manufacture tucatinib spray-dried dispersion or drug product intermediate (“Product”) for TUKYSA®. The Agreement provides that the Company will purchase Product pursuant to rolling forecasts and will purchase a minimum percentage of its requirements for Product from Hovione. The Agreement will remain in effect for an initial five-year term, followed by successive automatic two-year renewals. Either party may terminate the Agreement by written notice prior to commencement of the applicable renewal term. In addition, either party has the right to terminate the Agreement if the other party breaches the Agreement and does not remedy the breach after written notice or if the occurrence of a force majeure event prevents the other party from performing its obligations under the Agreement. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Agreement, which will be filed as an exhibit to the Company’s quarterly report on Form 10-Q for the quarter ending September 30, 2021.